Karan Takhar

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Bardavon partners with employers to support the health of their employees’ movement with both preventative and post-injury physical therapy solutions offered at work, in clinic, and at home. Bardavon is focused on the holistic musculoskeletal (MSK) health of the American worker through our nationwide, tech-enabled network of 25,000 physical and occupational therapists.

ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization. Combining proprietary gene editing tools and services, cGMP manufacturing capabilities, and industry-leading expertise, ElevateBio is enabling partners advance a breadth of therapeutic approaches and modalities including cell therapies, gene edited therapies, RNA therapies, mRNA vaccines, and more.

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.

VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.

Encoded Therapeutics is creating one-time, disease-modifying gene therapies for pediatric central nervous system (CNS) disorders with its cell-selective targeting and regulation platform. The Encoded approach offers potentially unprecedented gene specificity and cell selectivity to unlock novel opportunities by targeting a range of disease mechanisms. Encoded’s technology is compatible with any delivery system to control where and when therapeutic transgenes are expressed, thereby shaping the functionality of target cells and holding broader therapeutic potential beyond CNS disorders. For more information, please visit www.encoded.com, and follow us on LinkedIn, Twitter @EncodedTx and YouTube. Social media guidelines: https://encoded.com/social-media-community-guidelines/

Developing potentially best-in-class, novel small molecules targeting fundamental biological pathways in cancer

Koneksa is a leading patient-centric digital biomarker company for the pharmaceutical and biotechnology industries that develops end-to-end solutions for remotely collected clinical data. Koneksa supports agile decision-making in drug development and market strategy. By delivering integrated solutions for efficient trial designs that produce more meaningful data, Koneksa aims to revolutionize effect detection in clinical research.

Bardavon partners with employers to support the health of their employees’ movement with both preventative and post-injury physical therapy solutions offered at work, in clinic, and at home. Bardavon is focused on the holistic musculoskeletal (MSK) health of the American worker through our nationwide, tech-enabled network of 25,000 physical and occupational therapists.

ElevateBio is a technology-driven advanced therapy contract development and manufacturing organization (CDMO) powering the creation of life-transforming therapies. The company helps biopharmaceutical partners design, develop, and manufacture therapies from early discovery through commercialization. Combining proprietary gene editing tools and services, cGMP manufacturing capabilities, and industry-leading expertise, ElevateBio is enabling partners advance a breadth of therapeutic approaches and modalities including cell therapies, gene edited therapies, RNA therapies, mRNA vaccines, and more.

At Aura Biosciences, we are developing a new class of therapies to target and destroy cancer cells selectively, while leaving surrounding tissue unharmed – an approach we call molecular surgery. By safely eliminating cancer locally, we can treat early and transform the lives of people with a wide range of cancers that are poorly managed today. Our lead program in ocular melanoma (OM), also known as choroidal or uveal melanoma, is designed to remove cancer cells in the back of the eye as a first-line therapy, while allowing for the potential of preserving patients’ vision. The goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Development of a first-in-class, non-radioactive treatment option to selectively destroy cancer cells would create the possibility to transform the treatment of this and other cancers where the disease can be detected early. By enabling physicians to treat cancer more selectively, effectively and safely than they can do today, we aim to eliminate the need for invasive procedures that carry significant morbidity, including vision loss and often do little to improve a patient’s overall survival.

Matrix Capital Management is an investment management firm which manages private investment funds in a concentrated portfolio of high conviction investments, primarily in public companies. Matrix Capital was co-founded in 1999 by David Goel and is based outside of Boston, Massachusetts.